Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Actavis Group
Pharmaceutical company expects to deliver EBITDA margin above 26%
July 6th, 2005
Actavis Group hf. (ACT), the international generic pharmaceuticals company, announced its results for the quarter ended March 31, 2005. Actavis president & CEO, Robert Wessman made the following comments: [helv]As anticipated, this was a slower first quarter with few new product launches and several of our larger customers holding high inventory levels. The quarter is in line with our expectations with good progress made in the sale of own-label products with 14% growth. The first quarter of 2004 was exceptionally strong with three of the group's largest products (Ramipril in three forms) being launched in the period. It was also...
Source: Biotech Week (2005-07-06)
|
